RE: 6 Aug 2025 Summary6 Aug 2025 23:55
I like debating when it comes to investing / valuations - sometimes to test my thesis for any holes and sometimes to learn thesis on the other side (bear/bull) which I may have not realized. I am only pointing few points (take it as food for thoughts or ignore them) to the debate and you should do your own research or pick your own thesis and stick with it.. Hopefully this debate will continue to remain civil.
Relative valuation or peer comparison is not always straight forward. Its as good as someone arguing that apple and strawberries are both fruits, so they should have same priced, but do you get them for same prices? When it comes to stocks, for an apple to apple comparison, you should compare size category, growth, returns, margins before comparing valuation multiples. Market will clearly give more multiple to a higher growth or returns.
Also, STB is £200m market cap and Arbuthnot £166m. The argument that Lloyds is too big for CBG, doesn't a similar argument goes that CBG is in an entirely different size segment (mid-cap vs small-caps). Very few bank analysts follow these small caps, which in turn significantly reduces institutional following (also because of investable size). This is one of the reasons you will see majority of small cap companies in these market cap ranges, trade at significantly depressed multiples vs larger sized peers. Few are outliers, but for very different reasons. So, I really don't treat them as comparable for peer valuations. I have read various bank analyst reports and none of them list these direct comparable for valuation purposes.
For information, as per Reuters, CBG is covered by 10 bank analysts including RBC, Berenberg, UBS, Deutsche Bank, Shore Cap, Panmure etc. STB is covered by 3 small-cap analysts !!
A more appropriate peers from sizing perspective would be Investec, Lion Finance, TBC and perhaps Metro, that all fit into mid-cap category. But each have different end markets, growth, return, margin profiles and hence trade at different multiples, so its not easy to compare either.
Another point of view, if you want to still compare CBG with STB etc, why can one not argue that the whole pack (which was effected by motor financing) is undervalued or still discounted vs fair value given still looming uncertainties from FCA redressal? Also, reading through analyst reports (and I have read many), I think they still do not give any benefit of potential loan book growth, or reduced costs from management action and no more admin/advisor costs when the whole episode is resolved!!
And one more thing, none of the analysts compare CBG with these small-cap stocks!! I
I am long CBG and have done my homework (with clearly long bias clearly).